Business Context and Reporting Period
This Form 8-K is a current report filed by Aclaris Therapeutics, Inc. on September 27, 2019. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol ACRS. The filing serves as a Regulation FD disclosure regarding an upcoming corporate event.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event notification and does not contain financial statements or performance data.
Material Changes
No material financial changes versus prior periods are reported in this document. The filing focuses solely on the announcement of an R&D day event.
Guidance, Outlook, and Management Commentary
- Event Announcement: The Company announced it will host an R&D day in New York, New York, on September 27, 2019.
- Access: A live webcast of the event is available via the Investors section of the Company's website.
- Materials: A slide presentation was furnished as Exhibit 99.1.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the R&D day slide presentation (Exhibit 99.1) for potential updates on clinical trials or pipeline progress.
- Confirm the availability of the live webcast or archived recording on the Company's investor relations website.
- Note that this filing does not contain audited financial data; refer to the most recent 10-Q or 10-K for financial metrics.